Anti-S100B (Astrocyte and Melanoma Marker) [S100B/1012]

Catalog No.	Description		
AMA15-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system		
AMA15-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive TM Detection Systems and i6000 TM Automated Staining Systems		
MUA15-UC	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system		
MUA15-5UC	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system		
AXA15-YCD Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 160 tests			
AXA15-50D	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx [®] Elite/Ultra Staining System, 50 tests		

Clone	Species	Ig Class
S100B/1012	Mouse	IgG2a

Intended Use

For In Vitro Diagnostic Use. This antibody is designed for the specific localization of 100B in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

Summary and Explanation

S100B protein is part of the S100 family of proteins, which are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100B is a calcium binding peptide. S100B has been implicated in having many functions including neurite expansion, proliferation of melanoma cells, inhibition of protein kinase c-mediated phosphorylation, astrocytosis, axonal proliferation, inhibition of microtubule assembly and stimulation of Calcium ion fluxes. S100B is also associated with neurodegenerative diseases like Alzheimer's disease or other chronic neurological diseases. Apart from glial cell expression, S100B is also expressed in melanocytes, and can be used as a diagnostic tool for malignant melanoma.

Storage and Handling

Store at 2-8°C. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

Principles of the Procedure

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The primary antibody may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

Reagents Provided

Mouse Monoclonal Antibody to S100B is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations	
Control Tissue	Human Melanoma as available with Biogenex FB-A15M* & FG-A15M*	
Recommended Dilution for Concentrated Antibody	1:50-100 in HK941	
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK)	
Recommended Pretreatment (Xmatrx)	EZ-AR2 Elegance (HX032-YCD)	
Antibody Incubation (Manual/i6000)	30-60 min at RT	
Antibody Incubation (Xmatrx)	30-60 min at 25°C	
Detection System for Manual, Xmatrx & i6000 systems***	Use BioGenex Two-Step OR One-Step Super Sensitive TM Polymer-HRP IHC Detection System/DAB; see p. 2 for more information	

^{*}FB: positive control barrier slides, FG: positive control nonbarrier slides. Xmatrx requires barrier slides.

^{**}Pretreatment times will vary based on individual microwave power. ***For automation systems (Xmatrx-Elite, Xmatrx-Ultra & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Category	Antibodies	Revision No.	F
Document No.	932-A15M-EN	Release Date	June 01, 2021

Detection System	Two-Step HRP Kit	One-Step HRP Kit	Link and Label Kit	
System	QD440-XAKE	THU IN	Labertait	
	(1000 Test)	QD630-XAKE	QP300-XAKE	
	QD430-XAKE	(1000 Test)	(1000 Test)	
Manual	(1000 Test)			
Manual	QD420-YIKE			
	(500 Test)	QD620-XAKE	QP900-9LE	
	QD400-60KE	(500 Test)	(500 Test)	
	(60 Test)		, , ,	
Xmatrx -	QD550-YCDE	QD610-YADE	NT/A	
Automation	(200 Test)	(200 Test)	N/A	
i6000 -	QD410-YAXE	QD610-YAXE	N/A	
Automation	(200 Test)	(200 Test)	IN/A	
For more information, visit <u>www.biogenex.com</u> .				

Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or support@biogenex.com or your local distributor to report unusual staining.

Expected Results

This antibody stains nucleus/cytoplasm in positive cells in formalin-fixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medicallyestablished diagnostic product or procedure.

Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

Bibliography

- Yardan T1, Erenler AK, Baydin A, Aydin K, Cokluk C. Usefulness of S100B protein in neurological disorders. J Pak Med Assoc. 2011 Mar; 61(3):276-81.
- Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem. 2004 Jul; 37(7):512-8.
- Cocchia D, Michetti F, Donato R. Immunochemical and Immunocytochemical localization of S-100 antigen in normal human skin. Nature volume 294, pages85–87 (1981)
- Michetti F, Corvino V, Geloso MC, Lattanzi W, Bernardini C, Serpero L, Gazzolo D. The S100B protein in biological fluids: more than a lifelong biomarker of brain distress. J Neurochem. 2012 Mar; 120(5):644-59.
- Center for Disease Control. Decontamination of Laboratory Sink Drains to Remove Azide Salts. Center for Disease Control Manual Guide--Safety Management, No. CDC-22, Atlanta, Georgia. April 30, 1976.
- 6. Kiernan JA. Histological and Histochemical Methods: Theory and Practice. New York: Pergamon Press 1981.
- Nadji M, Morales AR. Immunoperoxidase, part 1: the techniques and its pitfall. Lab Med 1983; 14:767-770.
- Omata M, Liew CT, Ashcavai M, Peters Rl. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen. A possible source of error in immunohistochemistry. Am J Clin Pathol. May, 1980; 73(5):626-632.
- U.S. Congress, Clinical Laboratory Improvement Amendments of 1988: Final Rule, 57 FR 7163, February 28, 1992.
- 10. National Institute for Occupational Safety and Health, (NIOSH), Rockville, MD. Explosive azide hazard, Publication No. 78-127, 1976.

2°C 8°C	Temperature Limitation	IVD	In Vitro Diagnostic Medical Device
\boxtimes	Use By Date	LOT	Batch Code
NON	Non-Sterile	i	Consult Instructions for Use
EC REP	Representative in the European Community		Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	F
Document No.	932-A15M-EN	Release Date	June 01, 2021